A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast
Status:
Terminated
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to evaluate how well ferumoxtran-10, a new
Magnetic Resonance Imaging (MRI) contrast agent, can detect cancer in the pelvic lymph nodes
or malignant pelvic lymph nodes.